Clarient, Inc. And Definiens AG Collaborate To Develop Image Analysis Technology For Cancer Diagnostics

MUNICH, Germany & ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq:CLRT) and Definiens, Inc. jointly announced today that they established a strategic partnership to employ a series of image analysis platforms for Clarient’s in-house research and development, and Web-based customer portal PATHSiTESM. Under a five year collaborative agreement, Clarient and Definiens plan to develop and commercialize tools that will help to evaluate quantitative biomarkers that predict cancer treatment response to targeted therapies.